BIOLASE (NASDAQ:BIOL) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL) in a research report sent to investors on Thursday morning. The firm issued a sell rating on the medical technology company’s stock.

Separately, Benchmark reaffirmed a “speculative buy” rating and set a $0.40 target price on shares of BIOLASE in a report on Wednesday, October 2nd.

BIOLASE Stock Performance

NASDAQ:BIOL opened at $0.01 on Thursday. The business’s fifty day moving average is $0.01 and its 200 day moving average is $0.03. The firm has a market cap of $290,640.90, a price-to-earnings ratio of 0.00 and a beta of 0.67. BIOLASE has a 52-week low of $0.02 and a 52-week high of $1.94.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.